A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis | MicrobiomeTrials
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-15Est. Completion: 2030-03-31
Enrollment target: 100 participants
Locations
Children's Hospital Colorado, Aurora, Colorado, United States
University of South Florida, Tampa, Florida, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Northwell Health, Lake Success, New York, United States
NYU Langone Health, New York, New York, United States
Mater Hospital Brisbane, South Brisbane, Queensland, Australia
Royal Childrens Hospital, Parkville, Victoria, Australia
Perth Children's Hospital, Nedlands, Western Australia, Australia
CECIP - Centro de Estudos Clínicos do Interior Paulista, Jaú, São Paulo, Brazil
BR Trials - Pesquisa Clínica, São Paulo, São Paulo, Brazil
Hospital For Sick Children, Toronto, Ontario, Canada
Children's Hospital ZheJiang University School of Medicine, Hangzhou, Zhejiang, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
IATROS International, Bloemfontein, South Africa
Emmed Research, Pretoria, South Africa
National Taiwan University Hospital, Taipei, Taiwan
Other microbiome trials you might be interested in